GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14.
The agreement includes a $1.2 billion upfront payment along with an additional $800 million tied to future development and regulatory agreements.
As part of the deal, GSK will acquire Boston Pharmaceuticals’ subsidiary BP Asset IX to gain full rights to the drug. Efimosfermin, aimed at treating steatotic liver disease, is in late-stage trials and could reach the market by 2029.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.